Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sean P. Gavan, Alexander J. Thompson & Katherine Payne. (2018) The economic case for precision medicine. Expert Review of Precision Medicine and Drug Development 3:1, pages 1-9.
Read now
Read now
Jianying Dong, Arlene Sereno, Dikran Aivazian, Emma Langley, Brian R. Miller, William B Snyder, Eric Chan, Matt Cantele, Ronald Morena, Ingrid B.J.K. Joseph, Antonio Boccia, Cyrus Virata, James Gamez, Grace Yco, Michael Favis, Xiufeng Wu, Christilyn P. Graff, Qin Wang, Ellen Rohde, Rachel Rennard, Lisa Berquist, Flora Huang, Ying Zhang, Sharon X. Gao, Steffan N. Ho, Stephen J. Demarest, Mitchell E. Reff, Kandasamy Hariharan & Scott M. Glaser. (2011) A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. mAbs 3:3, pages 273-288.
Read now
Read now
Liu Hong, Shujun Li, Yu Han, Jianjun Du, Hongwei Zhang, Jipeng Li, Qingchuan Zhao, Kaichun Wu & Daiming Fan. (2011) Angiogenesis-related molecular targets in esophageal cancer. Expert Opinion on Investigational Drugs 20:5, pages 637-644.
Read now
Read now
Articles from other publishers (16)
Houqing Yin, Zequn Wang, Dan Wang, Muhadaisi Nuer, Mengyuan Han, Peng Ren, Shanwu Ma, Chutong Lin, Jingjing Chen, Haocheng Xian, Dongmei Ai, Xuejun Li, Shaohua Ma, Zhiqiang Lin & Yan Pan. (2023) TIMELESS promotes the proliferation and migration of lung adenocarcinoma cells by activating EGFR through AMPK and SPHK1 regulation. European Journal of Pharmacology 955, pages 175883.
Crossref
Crossref
Chen Sun, Huimin Zhao, Wei Li, Yudi Jia, Yi Yang, Ying Peng & Jiang Zheng. (2021) Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate. Drug Metabolism and Disposition 49:10, pages 892-901.
Crossref
Crossref
Huiyan Deng, Junying Liu, Xiaojin Duan & Yueping Liu. (2018) The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma. Pathology - Research and Practice 214:3, pages 450-454.
Crossref
Crossref
Justyna Rawluk & Cornelius F. Waller. 2018. Small Molecules in Oncology. Small Molecules in Oncology
235
246
.
Khalid Abu Ajaj. (2017) A decade of targeted therapy for non-small cell lung cancer. Journal of Pulmonology and Respiratory Research 1:1, pages 023-027.
Crossref
Crossref
Fiona K. Middleton, Miranda J. Patterson, Claire J. Elstob, Sarah Fordham, Ashleigh Herriott, Mark A. Wade, Aiste McCormick, Richard Edmondson, Felicity E.B. May, James M. Allan, John R. Pollard & Nicola J. Curtin. (2015) Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget 6:32, pages 32396-32409.
Crossref
Crossref
Godfrey Essien Etokebe, Shanbeh Zienolddiny, Zeljko Kupanovac, Morten Enersen, Sanja Balen, Veljko Flego, Ljiljana Bulat-Kardum, Anđelka Radojčić-Badovinac, Vidar Skaug, Per Bakke, Aage Haugen & Zlatko Dembic. (2015) Association of the FAM46A Gene VNTRs and BAG6 rs3117582 SNP with Non Small Cell Lung Cancer (NSCLC) in Croatian and Norwegian Populations. PLOS ONE 10:4, pages e0122651.
Crossref
Crossref
R F Dielschneider, W Xiao, J-Y Yoon, E Noh, V Banerji, H Li, A J Marshall, J B Johnston & S B Gibson. (2014) Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling. Cell Death & Disease 5:10, pages e1439-e1439.
Crossref
Crossref
Petra Martin, Scott P Owen & Natasha B Leighl. (2013) Gefitinib: re-emerging from the shadows. Lung Cancer Management 2:5, pages 423-437.
Crossref
Crossref
AKIHIKO SANO, SHINJI SAKURAI, HIROYUKI KATO, SHIGEMASA SUZUKI, TAKEHIKO YOKOBORI, MAKOTO SAKAI, NARITAKA TANAKA, TAKANORI INOSE, MAKOTO SOHDA, MASANOBU NAKAJIMA, YASUYUKI FUKAI, TATSUYA MIYAZAKI, HITOSHI OJIMA, YOSHINORI HOSOYA, TAKEHIKO ENOMOTO, TATSUO KANDA, YOICHI AJIOKA & HIROYUKI KUWANO. (2013) Expression of receptor tyrosine kinases in esophageal carcinosarcoma. Oncology Reports 29:6, pages 2119-2126.
Crossref
Crossref
Tom Gani Sutedja. 2013. Principles and Practice of Interventional Pulmonology. Principles and Practice of Interventional Pulmonology
337
341
.
Shinji Kuroda, Tomohisa Yokoyama, Justina Tam, Ailing Scott, Li Ma, Manish Shanker, Jiankang Jin, Corbin Goerlich, David Willcutts, Jack Roth, Konstantin Sokolov, Keith Johnston & Rajagopal Ramesha. 2012. Pulmonary Nanomedicine. Pulmonary Nanomedicine
15
44
.
Tapan K Mukherjee, Karan Paul & Srirupa Mukhopadhyay. (2011) Cell signaling molecules as drug targets in lung cancer: an overview. Current Opinion in Pulmonary Medicine 17:4, pages 286-291.
Crossref
Crossref
Rong Wang & Roderick H. Dashwood. (2011) Endothelins and their receptors in cancer: Identification of therapeutic targets. Pharmacological Research 63:6, pages 519-524.
Crossref
Crossref
Katsuhiro Masago, Shiro Fujita, Yosuke Togashi, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Hiroki Nagai, Yuichi Sakamori, Tadashi Mio & Michiaki Mishima. (2011) Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib Therapy. Clinical Lung Cancer 12:1, pages 56-61.
Crossref
Crossref
A. C. MacKinnon, J. Kopatz & T. Sethi. (2010) The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies. British Medical Bulletin 95:1, pages 47-61.
Crossref
Crossref